Insider buying last 90 days
No open-market insider purchases were filed for BMRN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BMRN insider filing, plotted on the chart in Gekko.Open BMRN in Gekko
NASDAQ: BMRN
BioMarin Pharmaceutical (BMRN) Stock Analysis & Forecast
Sep 28 close
$59.46−0.80 (−1.3%)
Gekko Brief
AI summaryBioMarin's recent coverage centers on its rare-disease pipeline and second-quarter results, where EPS of $1.20 beat the $0.95 estimate and revenue grew 20% year-over-year. J.P. Morgan has maintained a Buy rating with an $86 price target, and commentary points to potential catalysts including BMN 351 Phase 1/2 data in Duchenne muscular dystrophy by year-end 2026 and a possible approval of Voxzogo for hypochondroplasia in the first half of 2027. Coverage also notes the stock trading near its 52-week low despite the earnings beat.
BMRN closed at $59.46, down 1.3%, sitting between its 50-day average of $63.99 and 200-day average of $58.56, with a 52-week range of $49.26 to $70.98. The GekkoIndex reads 68.8, placing the stock in the Accumulation zone. Price sits 13.7% below Gekko Fair Value of $68.89. One-month return is -8.9%, while three-month and six-month returns stand at 3.1% and 9.8% respectively.
BioMarin reports earnings on 26 October 2026 after close, 27 days away and within a typical 20-trading-day holding window; the prior report produced a 6.5% reaction, with six beats in the last eight quarters. Options activity shows one unusual signal in the last 30 days, with call premium of $331,530 and no put premium recorded. Consensus among 22 covering firms includes 17 buy and 5 hold ratings, with a consensus target of $91.62. Seasonality over five years shows a 0% average 20-day return from this point, with gains in three of those years.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
BioMarin Pharmaceutical price vs fair value
Close $59.46200-day averageGekko Fair Value $68.89
BioMarin Pharmaceutical quick facts
- Market cap
- $11.49B
- P/E ratio
- 170.4
- Forward P/E
- 9.4
- EPS, TTM
- $0.36
- Revenue, TTM
- $3.41B
- Profit margin
- 2.1%
- Dividend yield
- —
- Beta
- 0.24
- Volume
- 2.36M avg 2.02M
- 1-year return
- +13.0%
- Typical daily move
- ±2.6%
- Typical 20-day move
- ±5.2%
- 50-day average
- $63.99
- 200-day average
- $58.56
- Next earnings
- Oct 26 after close
- Shares outstanding
- 193.6M
BioMarin Pharmaceutical swing-trade checklist
BioMarin Pharmaceutical scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $59.46 sits between the 50-day ($63.99) and 200-day ($58.56) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
68.8, Accumulation
Reading 68.8 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
13.7% below
Price is 13.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 30 days: 1 unusual options signal.
See smart money - Earnings riskheadwind
Reports in 27 days
Reports on Oct 26, 2026, 27 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
0.0% on average
From this point in the calendar, the next 20 trading days averaged 0% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
BioMarin Pharmaceutical stock chart and price history
BioMarin Pharmaceutical closed at $59.46 on Sep 28, 2026, +13.0% over the past year, inside a 52-week range of $49.26 to $70.98.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −8.9%
- 3 months
- +3.1%
- 6 months
- +9.8%
- 1 year
- +13.0%
The full BMRN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BMRN in Gekko
Follow BioMarin Pharmaceutical through every session
Put BMRN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BMRN in GekkoFree for 7 days. No credit card required.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical develops and sells medicines for people with rare, often life-threatening genetic and metabolic disorders. Its marketed products include enzyme replacement therapies such as Vimizim, Naglazyme, Brineura and Aldurazyme, along with Kuvan and Palynziq for phenylketonuria and Voxzogo for achondroplasia. The company is best known for this concentrated focus on treatments for small, clearly defined patient populations rather than broader disease categories.
Alongside its approved therapies, BioMarin runs a pipeline of experimental treatments, including a gene therapy for severe hemophilia A now in Phase III trials and earlier-stage gene therapy programs aimed at phenylketonuria and primary hyperoxaluria. It sells through specialty pharmacies, hospitals, government health agencies, and distributors and wholesalers, reaching patients and providers in the United States, Europe, Latin America and other regions. The company also works with outside partners, including Sarepta Therapeutics, Ares Trading, Catalyst Pharmaceutical Partners and Asubio Pharma, on licensing and collaborative projects.
BioMarin was founded in 1996 and is headquartered in San Rafael, California. Its shares are listed on the NASDAQ under the ticker BMRN.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- biomarin.com
BioMarin Pharmaceutical GekkoIndex: the smart money zone
BioMarin Pharmaceutical’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 68.8, in the Accumulation zone, up 8.1 points over five sessions.
68.8Accumulation
Up 8.1 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 53 | +1.1% | +2.4% | ||
| Accumulation (current zone) | 250 | −0.1% | −0.2% | ||
| Neutral | 348 | −0.4% | −1.2% | ||
| Distribution | 18 | −1.9% | −6.2% | ||
| Selling | 3 | Too few readings yet | |||
Average BMRN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the BMRN price, zone by zone.Track BMRN in Gekko
Is BioMarin Pharmaceutical stock overvalued? Gekko Fair Value
BioMarin Pharmaceutical trades 13.7% below Gekko Fair Value of $68.89, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what BioMarin Pharmaceutical shares are worth, recalculated every trading day.
$68.89
Gekko Fair Value, Sep 26, 2026
13.7% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open BMRN in Gekko
BioMarin Pharmaceutical insider and Congress trading
No open-market insider purchases were filed for BioMarin Pharmaceutical, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BMRN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BMRN, plotted on the chart in Gekko.Open BMRN in Gekko
Buybacks
BioMarin Pharmaceutical has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $28.18M
- As a share of market cap
- 0.25%
From company filings.
Unusual options activity last 30 days
1signal, 100% of the flagged premium in calls.
Latest: Bullish flow on Aug 29, $332K in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds BMRN.
1added0opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
BioMarin Pharmaceutical earnings: next date and track record
BioMarin Pharmaceutical reports on Oct 26, 2026, after the close (27 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Oct 26, 2026
Expected after the close, 27 days away
- EPS estimate
- $1.34
- Revenue estimate
- $1.02B
6 of 8reports beat the EPS estimate
±4%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $1.20 est $0.95 | $989.7M est $932.0M | +6.5% |
| May 4, 2026 | $0.76 est $0.91 | $766.0M est $752.5M | −1.5% |
| Feb 23, 2026 | $0.46 est $0.81 | $874.6M est $833.7M | −2.3% |
| Oct 27, 2025 | $0.12 est −$0.15 | $776.1M est $823.5M | −1.8% |
| Aug 4, 2025 | $1.44 est $0.86 | $825.4M est $761.9M | +6.5% |
| May 1, 2025 | $1.13 est $0.95 | $745.1M est $738.7M | −2.6% |
| Feb 19, 2025 | $0.92 est $0.74 | $747.0M est $712.3M | +6.0% |
| Oct 29, 2024 | $0.55 est $0.52 | $745.7M est $712.3M | −4.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
BioMarin Pharmaceutical stock forecast and analyst price targets
Analysts’ average 12-month price target for BioMarin Pharmaceutical is $91.62, +54.1% from the last close, from 22 firms rating the stock in the last 90 days.
$91.62consensus 12-month target, +54.1% from the last close
Now $59.46Avg $91.62
Low $60High $124
Each firm’s latest rating in the last 90 days: 22 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 21 | J.P. Morgan | $86 | +44.6% |
| Sep 17 | Guggenheim | $86 | +44.6% |
| Sep 16 | BMO Capital | $97 | +63.1% |
| Sep 16 | Morgan Stanley | $124 | +108.5% |
| Sep 15 | BMO Capital | $97 | +63.1% |
−0.2%average 20-day move after past Accumulation readings
0.0%average move over the next 20 trading days in the last 5 years
±2.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
BioMarin Pharmaceutical seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, BioMarin Pharmaceutical averaged 0.0% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.8% | 3 of 5 |
| Next 10 trading days | +0.8% | 3 of 5 |
| Next 15 trading days | +0.2% | 2 of 5 |
| Next 20 trading days | 0.0% | 3 of 5 |
| Next 30 trading days | −1.3% | 1 of 5 |
For scale, BMRN’s typical 20-trading-day move in either direction is about 5.2%.
BioMarin Pharmaceutical market cap and key statistics
BioMarin Pharmaceutical’s market cap is $11.49B, with a P/E ratio of 170.4 and revenue of $3.41B over the last twelve months.
Valuation
- Market cap
- $11.49B
- P/E ratio
- 170.4
- Forward P/E
- 9.4
- EPS, TTM
- $0.36
- Gekko Fair Value
- $68.89
Trading
- Volume
- 2.36M
- Avg volume, 20 days
- 2.02M
- 52-week high
- $70.98
- 52-week low
- $49.26
- Shares outstanding
- 193.6M
Financials
- Revenue, TTM
- $3.41B
- Profit margin
- 2.1%
- Return on equity
- 1.2%
- Quarterly earnings growth, YoY
- −81.3%
Risk and income
- Beta
- 0.24
- Typical daily move
- ±2.6%
- Typical 20-day move
- ±5.2%
BioMarin Pharmaceutical stock news this week
Coverage of BioMarin Pharmaceutical this week reads neutral: 1 positive, 3 neutral and 0 negative headlines.
- BioMarin Pharmaceutical Inc. (BM8.F) stock price, news, quote and historyYahoo Finance UK, Sep 23
- BioMarin Pharmaceutical stock holds at $63.94 as analysts stay bullishAD HOC NEWS, Sep 23
- BioMarin Pharmaceutical stock holds near its 52-week lowAD HOC NEWS, Sep 22
- BioMarin Pharmaceutical Inc. (BMRN) stock price, news, quote and historyYahoo Finance Singapore, Sep 22
- BioMarin: Why I See Significant Upside Into 2027Seeking Alpha, Sep 21
BioMarin Pharmaceutical peers
BioMarin Pharmaceutical’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
BioMarin Pharmaceutical stock FAQ
What is BioMarin Pharmaceutical’s market cap?
BioMarin Pharmaceutical’s market cap is $11.49B at the Sep 28, 2026 close of $59.46, with 193.6M shares outstanding. The shares trade on a P/E ratio of 170.4.
What is the BioMarin Pharmaceutical stock forecast?
The consensus analyst 12-month price target for BioMarin Pharmaceutical is $91.62, +54.1% from the last close. Of the 22 firms that rated the stock in the last 90 days, 17 rate it a buy, 5 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is BioMarin Pharmaceutical stock overvalued or undervalued?
On Gekko’s estimate BioMarin Pharmaceutical is undervalued: the Sep 28, 2026 close of $59.46 is 13.7% below Gekko Fair Value of $68.89. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does BioMarin Pharmaceutical report earnings next?
BioMarin Pharmaceutical is expected to report on Oct 26, 2026, after the market closes (27 days away). Analysts expect earnings of $1.34 per share on revenue of $1.02B. BioMarin Pharmaceutical beat the earnings estimate in 6 of its last 8 reports, moving 4% on average across the report.
What is BioMarin Pharmaceutical’s 52-week high and low?
BioMarin Pharmaceutical’s 52-week high is $70.98 and its 52-week low is $49.26; it closed at $59.46 on Sep 28, 2026, +13.0% over the past year. Over the last five years the shares peaked at $117.77 on Jan 27, 2023.
Is BioMarin Pharmaceutical stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (gekkoindex, fair value and smart money), 2 as mixed (trend and seasonality) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in BioMarin Pharmaceutical?
Gekko flagged 1 unusual options signal in BioMarin Pharmaceutical over the last 30 days, with $332K of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Aug 29, 2026 with $332K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See BioMarin Pharmaceutical the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.